The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: A tale of two receptors

Blood Purification

Volumn 29, Issue 2, 2010, Pages 86-92

  Brines, Michael ^a  

^a Warren Pharmaceuticals Inc   (United States)

Author keywords

Apoptosis; Cytokines; Cytoprotection; Erythropoietin; Inflammation; Innate immune response; Ischemia; Necrosis; Trauma; Wound healing

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; JANUS KINASE 2; RECOMBINANT ERYTHROPOIETIN;

ALLERGIC ENCEPHALOMYELITIS; BLUNT TRAUMA; BONE MARROW; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; CELL DAMAGE; CELL PROTECTION; DIABETIC NEPHROPATHY; DRUG MEGADOSE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; INFLAMMATION; KIDNEY INJURY; METABOLIC STRESS; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; THROMBOCYTOPOIESIS; THROMBOSIS; URETER OBSTRUCTION; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANIMALS; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; CYTOKINES; DRUG DESIGN; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEEDBACK, PHYSIOLOGICAL; HEMATINICS; HEMATOPOIESIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; JANUS KINASE 2; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, ERYTHROPOIETIN; REPERFUSION INJURY; STAT TRANSCRIPTION FACTORS; STRESS, PHYSIOLOGICAL; WOUNDS AND INJURIES;

EID: 77749317193     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245630     Document Type: Review

References (29)

1. Brines M, Cerami A: Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494.
2. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tor M, Billiar T: The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007; 220: 60-81.
3. La Ferla K, Reimann C, Jelkmann W, Hellwig-Burgel T: Inhibition of erythropoietin gene expression signaling involves the transcription factors Gata-2 and NF-kappaB. FASEB J 2002; 16: 1811-1813.
4. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-651.
5. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952: 128-134.
6. Brines M, Cerami A: Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-432.
7. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU: Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60: 386-392.
8. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995; 92: 3717-3720.
9. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M: Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-676.
10. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
11. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R: Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998; 253: 26-32.
12. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-975.
13. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
14. Chatterjee PK: Novel pharmacological approaches to the treatment of renal ischemiareperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 1-43.
15. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348-355.
16. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18: 15-20.
17. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LO, Cerami-Hand C, Wuerth JP, Cerami A, Brines M: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741-6746.
18. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
19. Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA: Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; 27: 2353-2361.
20. Jelkmann W: Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007; 78: 183-205.
21. Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS: NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 1998; 5: 861-866.
22. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
23. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268: 11208-11216.
24. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008; 105: 10925-10930.
25. Fliser D, Haller H: Erythropoietin and treatment of non-anemic conditions - cardiovascular protection. Semin Hematol 2007; 44: 212-217.
26. Satake R, Kozutsumi H, Takeuchi M, Asano K: Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta 1990; 1038: 125-129.
27. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
28. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L: Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007; 27: 552-563.
29. Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A: Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 2008; 17: 135-141.